TBRG1 and B-cell non-Hodgkin lymphoma: Our data, together with the recent observation that NIAM-deficient mice are predisposed to malignant transformation suggest that NIAM is a crucial target for the oncogenic effects of miR-155 in B-cell lymphoma.